The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,556.00
Bid: 12,588.00
Ask: 12,590.00
Change: -34.00 (-0.27%)
Spread: 2.00 (0.016%)
Open: 12,626.00
High: 12,646.00
Low: 12,474.00
Prev. Close: 12,590.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 5-With new Omicron case detected, UK awaits COVID booster advice

Sun, 28th Nov 2021 09:34

* UK wants to broaden booster campaign

* New measures are temporary

* Scotland also to introduce travel measures
(Adds new measures for some schoolchildren)

By Elizabeth Piper

LONDON, Nov 28 (Reuters) - Britain's health minister Sajid
Javid said on Sunday he expected to receive advice imminently on
whether the government can broaden a booster shot programme to
try to weaken the impact of the newly identified Omicron
coronavirus variant.

A day after Britain said it had detected two cases of the
variant, its health agency recorded a third - in a person who
was linked to travel to Southern Africa but had since left the
country after spending time in the capital London.

The government announced new measures on Saturday to try to
slow the spread of the variant, toughening rules for people
arriving into Britain and ordering the use of masks in retail
settings and on transport in England. Some schoolchildren will
also be required to wear face coverings in communal areas.

But ministers also want to ramp up the offer of booster
jabs, saying even if vaccines prove to be less effective against
Omicron, they should offer better protection against it and
reduce the number of hospitalisations and deaths.

"The other thing that still remains hugely important, but I
think it's fair to say now more important than it was before, is
our vaccination programme," Javid told Sky News.

"That is why I have also asked our expert advisers on
vaccines called JCVI (the Joint Committee on Vaccination and
Immunisation) to give me very quick advice on broadening,
boosting our booster programme, and I expect to get that advice
imminently."

Earlier this month, Britain expanded eligibility for booster
jabs to people in their 40s and also said children aged 16 and
17 would be able to receive a second dose following guidance
from the JCVI.

Scotland, where the government sets its own health rules,
already requires people to wear face coverings and work from
home if possible. First Minister Nicola Sturgeon told the BBC's
Andrew Marr show she would also bring in new rules for arrivals.

"I think we need to be open minded to doing anything
required to keep the population safe right now," she said.

BUYING TIME

The discovery of Omicron, dubbed a "variant of concern" last
week by the World Health Organization, has caused worry around
the world https://www.reuters.com/world/new-coronavirus-variant-omicron-keeps-spreading-australia-detects-cases-2021-11-28
that it could resist vaccinations and prolong the nearly
two-year COVID-19 pandemic.

Almost 145,000 people have died from COVID-19 in Britain,
with Johnson's government criticised for moving too slowly in
the early days of the pandemic. Since then, the government has
tried to react quickly to the appearance of new variants.

Javid said the new measures were needed to buy time for
experts to understand more about Omicron, which is likely to
have spread in Britain beyond the three cases so far detected.

Jenny Harries, chief executive of the UK's Health Security
Agency, said: "It is very likely that we will find more cases
over the coming days."

Paul Burton, chief medical officer at Moderna, said
that if a new vaccine was needed, "I think that's going to be
early 2022 before that’s really going to be available in large
quantities".

Javid said it was not as yet clear whether vaccines were
less effective against the variant.

"The point is the vaccines are still going to give you more
protection than otherwise," he said. "That is why the booster
programme is so important."
(Reporting by Elizabeth Piper, Editing by Louise Heavens, Mark
Heinrich, Raissa Kasolowsky and Catherine Evans)

More News
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.